Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia
| Autor: | John Swansbury, Alison Morilla, Sonia Maravelaki, Vasantha Brito-Babapulle, Ricardo Morilla, K Owusu-Ankomah, Anna Burford, Ilaria Del Giudice, Roger A'Hern, Estella Matutes, Daniel Catovsky, Nnenna Osuji |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Pathology Chronic lymphocytic leukemia chemical and pharmacologic phenomena Stem cell marker Gastroenterology Risk Factors Internal medicine medicine Biomarkers Tumor Humans Stage (cooking) In Situ Hybridization Fluorescence Aged Aged 80 and over ZAP-70 Protein-Tyrosine Kinase medicine.diagnostic_test biology business.industry Surrogate endpoint Cancer hemic and immune systems Middle Aged medicine.disease Flow Cytometry Prognosis ADP-ribosyl Cyclase 1 Leukemia Lymphocytic Chronic B-Cell Oncology biology.protein Female Antibody business Trisomy Fluorescence in situ hybridization |
| Popis: | zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia BACKGROUND. xi-Chain associated protein (ZAP)-70 has been proposed as a surrogate marker for immunoglobulin heavy-chain variable region (IgVH) mutation in chronic lymphocytic leukemia (CLL), but it is still not clear whether it is an independent prognostic factor. METHODS. The authors evaluated ZAP-70 expression by flow cytometry in 201 untreated patients and correlated ZAP-70 levels with CD38 expression, genetic abnormalities detected by fluorescence in situ hybridization (FISH), and the time from diagnosis to first treatment. RESULTS. Fifty-seven patients (28%) were positive for ZAP-70 (>= 20%). Positive ZAP-70 status was associated with advanced disease stage, atypical morphology, CD38-positive status, trisomy 12, del(6q), or no detectable abnormalities; negative ZAP-70 status was correlated with del(13q) as a sole abnormality. The treatment-free interval (TFI) was 17.7 months for ZAP-70-positive patients and 44.6 months for ZAP-70-negative patients (P = 7%, and the absence of del(13q) as a sole abnormality as independent factors for short TFI. Excluding FISH, ZAP-70 status acquired independent prognostic value along with CD38 status. The authors proposed a risk model that combines ZAP-70 and CD38 to identify patients who are likely to progress. When both markets were positive, the TFI was 12 months; when both were negative, the median TFI was 54 months; a median TFI of 26 months was observed in patients who had discordant results (P < 0.00001). CONCLUSIONS. The current findings suggested that both ZAP-70 and CD38 should be tested prospectively in all patients with early-stage CLL. (c) 2005 American Cancer Society. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|